JohnLaurielloMD

Psychiatry • Philadelphia, PA

Professor and Chairman, Department of Psychiatry and Human Behavior, Sidney Kimmel Medical College-Jefferson Health

Join to view full profile

Dr. Lauriello is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lauriello's full profile

Already have an account?

Office
833 Chestnut St
Ste 210
Philadelphia, PA 19107
Phone+1 215-955-6913

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Psychiatry, 1986 - 1990
Lewis Katz School of Medicine at Temple UniversityClass of 1986

Certifications & Licensure

CA State Medical License 1990 - 2025
PA State Medical License 2019 - 2024
MO State Medical License 2009 - 2020
NM State Medical License 1994 - 2010
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Cerner Modular EHR, Cerner Corporation, 2013

Clinical Trials

Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone Start of enrollment: 2010 Jul 01
Completed
Phase 3

Publications & Presentations

PubMed

17 citations
Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis.
Kate Merritt, Robert A McCutcheon, André Aleman, Sarah Ashley, Katherine Beck
Molecular Psychiatry. 2023-05-01
11 citations
Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.
Leslie Citrome, Sheldon H Preskorn, John Lauriello, John H Krystal, Rishi Kakar
The Journal of Clinical Psychiatry. 2022-10-03
6 citations
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia.
John Lauriello, Peter J. Weiden, Carole D. Gleeson, Ankit Shah, Luke Boulanger
CNS Drugs. 2021-09-21

Other

Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs
Lauriello J, Campbell AR
http://www.uptodate.com/contents/pharmacotherapy-for-schizophrenia-long-acting-injectable-antipsycho
UpToDate, Wolters Kluwer Health - 2013-02-14

Press Mentions

How to Recognize Tardive DyskinesiaOctober 3rd, 2024
Assessing Tardive Dyskinesia RiskSeptember 5th, 2024
Aripiprazole Lauroxil Appears to Improve Schizophrenia Symptoms Safely, SignificantlyAugust 26th, 2020